explore -WSS

explore

author：knowledge 2025-09-29 01:46:06 - browse：3

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Weight loss drugs aren’t covered by Obamacare. That may change

explore

WSS

Americans' trust in science, scientist continues decline: Report

FDA approves world's first CRISPR

New study raises questions about niacin and heart health

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

AI models in health care face new federal disclosure requirements

In 'major milestone,' FDA approves first cell therapy for solid tumors

Wikipedia

explore

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Opioid cravings were reduced by anti

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

George Santos makes 1st court appearance after pleading not guilty to 13 counts

AI models in health care face new federal disclosure requirements

Alkermes shareholders re

WATCH: Why do our ears pop?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Researchers tackle phage therapy hurdles for wider adoption

focus

Pfizer plans to depart BIO

AI models in health care face new federal disclosure requirements

FDA approves world's first CRISPR

Radiology is caught between AI's potential and concern for patients

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Abridge raises $150m as clinical notes automation market heats up

explore

hotspot

focus

Wikipedia